Nykode Therapeutics Announces Issuance of Key Patent for Individualized Neoantigen-Based Vaccines

OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled “Therapeutic Anticancer Neoepitope Vaccine.”

The newly issued patent describes Nykode’s fully individualized neoantigen-based vaccine, VB10.NEO, which is in development for the treatment of locally advanced or metastatic solid tumors. The 20-year expiration date of this patent is January 5, 2037. Related patents were previously granted to the company in Russia, India and Australia.